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1182LBH589 Enhances T Cell Activation In Vivo and
Accelerates Graft-versus-Host Disease in Mice
Dapeng Wang,1 Cristina Iclozan,1 Chen Liu,2 Changqing Xia,2 Claudio Anasetti,3
Xue-Zhong Yu1,3,4Histone deacetylase inhibitors (HDACis) are a new class of compounds that induce acetylation of histone
lysine tails in chromatin and modify gene expression. The Food & Drug Administration approved HDACi,
Vorinostat, or suberoylanilide hydroxamic acid (SAHA), has been shown to inhibit tumor cell growth and
the production of proinflammatory cytokines. In preclinical allogeneic transplant models, SAHA induces
graft-versus-host disease (GVHD) amelioration in treated mice without impairing graft-versus-leukemia.
LBH589 (Panobinostat), a structurally novel cinnamic hydroxamic acid class, is an HDACi more potent
than SAHA. In the current work, we tested the hypothesis that LBH589 would be highly effective in the pre-
vention of GVHD. Using mouse model of allogeneic bone marrow transplant (BMT), we unexpectedly found
that treatment with LBH589 accelerated GVHD, in contrast to the treatment with SAHA that alleviated
GVHD. Accelerated GVHD in the recipients treated with LBH589 was associated with elevated Th1 cyto-
kines in recipient serum, enhanced CXCR3 expression on donor T cells, and T cell infiltration in the liver.
The current study highlights the distinct effects of pan HDACi on allogeneic BMT and alerts that LBH589
(Panobinostat) could have an adverse effect on GVHD, and possibly on other inflammatory diseases.
Biol Blood Marrow Transplant 18: 1182-1190 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Histone deacetylase inhibitor, Graft-versus-host disease, T cells, CytokineINTRODUCTION
Histone deacetylase (HDAC) are enzymes that
modulate chromatin structure and gene expression by
removing acetyl groups on histone and other
proteins. According to their structure, HDACs are
classified into 4 groups: class I (HDAC1, HDAC2,
HDAC3, and HDAC8), class IIa (HDAC4, HDAC5,
HDAC7, and HDAC9), class IIb (HDAC6 and
HDAC10), class III (SIRT1-7), and class IV
(HDAC11) [1,2]. Inhibiting HDAC activity by pan-
HDAC inhibitors (HDACis) has been shown to cause
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oi.org/10.1016/j.bbmt.2012.06.002initially, pan-HDACis were applied for cancer ther-
apy. Recent findings showed that pan-HDACi could
also prevent or alleviate inflammation inmousemodels
for various diseases as colitis, lupus, arthritis, and neu-
ral stroke [3-6]. Li et al. [5], Reddy et al. [7,8], and Leng
et al. [9], showed that SAHA, a pan-HDACi approved
for the therapy of cutaneous T cell lymphoma, could
alleviate graft-versus-host disease (GVHD) after allo-
geneic bone marrow transplant (BMT) in mice in an
indoleamine 2,3-dioxygenase-dependent manner.
LBH589 is a hydroxamic acid-based HDACi with
a similar structure with suberoylanilide hydroxamic
acid (SAHA). Compared to SAHA, LBH589 has
much higher potency in inhibiting each ofHDAC fam-
ily members [10]. In the current study, we evaluated
the effect of LBH589 on the prevention of GVHD af-
ter allogeneic BMT, and unexpectedly we found that
LBH589 worsened GVHD. The accelerated GVHD
was related to higher levels of proinflammatory cyto-
kines in serum, and increased CXCR3 expression on
donor T cells, and T cell infiltration in the liver.MATERIALS AND METHODS
Mice
C57BL/6 (B6, H-2b), BALB/c (B/c, H-2d), were
purchased from National Cancer Institute/National
Biol Blood Marrow Transplant 18:1182-1190, 2012 1183HDACs in GVHDInstitutes of Health. All animals were housed in an
American Association for Laboratory Animal Care-
accredited Animal Resource Center at Moffitt Cancer
Center. Experiments were carried out under protocols
approved by the Institutional Animal Care and Use
Committee.
Chemicals and Reagents
LBH589 powder provided by Novartis AG was
dissolved in 5% dextrose (Sigma-Aldrich, St. Louis,
MO) and sonicated in PBS before use. SAHA was pur-
chased from ChemieTek (Indianapolis, IN). SAHA
was first dissolved in DMSO and further diluted in
PBS before use. LBH589 and SAHA were adminis-
trated via i.p. injection. Carboxyfluorescein diacetate,
succinimidyl ester (CFSE)-5 and 6 was purchased
from Invitrogen (Grand Island, NY).
Isolation of Donor Tand BM Cells
DonormiceT cells were purified by negative selec-
tion from pooled spleen and lymph node cells to re-
move the non-T cells using biotinylated Abs and the
MACS system (anti-biotinmicrobeads and LS column,
Miltenyi Biotech, Auburn, CA) according to themanu-
facture’s instruction. The Abs for T cell purification
(anti-mouse TER-119, anti-mouse CD49b, anti-
mouse CD11b, and anti-human/mouse CD45R) were
purchased from eBioscience (San Diego, CA). The pu-
rity ofT cellswas usually over 95%.Bonemarrow (BM)
was harvested from tibia and femurs, and T cells were
depleted by incubation with anti-Thy1.2 Ab (clone
30H12, BioXCell, West Lebanon, NH), and rabbit
complement (GTI Diagnostics, Waukesha, WI).
BMT
Female B/c mice at 7 to 8 weeks old were lethally
irradiated (800 cGy, single dose) using a Shepherd
Mark I Cesium Irradiator (J.L. Shepherd and Associ-
ates, San Fernando, CA) 1 day before BMT. On the
day of transplantation (Day 0), 5 106T cell depleted
(TCD) B6 BM cells were transferred to recipients via
tail vein with or without 1  106 B6 T cells. Mice
were housed in sterilized micro isolator cages and re-
ceived normal chow and autoclaved hyperchlorinated
water for the first 3 weeks after BMT and autoclaved
water thereafter. The clinical signs of GVHD (weight
loss, ruffled fur, hunched back, and skin lesions) were
monitored twice a week.
Abs and Flow Cytometry
The following antibodies were used for cell surface
staining: anti-CD4 FITC, or APC (L3T4), anti-CD8a
FITC, APC, APC-Cy7 or Alexa Fluor 700 (Ly-2),
anti-H-2Kb FITC, PE, or biotin (AF6), anti-mouse
CD11b PE-Cy7, anti-mouse CD11c PE, anti-mouse
Ly6G (Gr-1) biotin, and anti-mouse CXCR3 biotinwere purchased from eBioscience; anti-mouse CCR6
APC were purchased from BioLegend (San Diego,
CA); anti-CD4 Pacific blue (RM4-5) and anti-mouse
a4b7 PE was purchased from BD Biosciences (San
Jose, CA). Detection of biotinylated Abs was per-
formed using APC-Cy7 or APC conjugated to strepta-
vidin (BD Biosciences). Flow data were acquired on
FACSCalibur, or LSR II (BD Biosciences) and ana-
lyzed using FlowJo (TreeStar Inc, Ashland, OR).
Measurement of Tand B Cell Function
Splenic cells were cultured in RPMI 1640 media
(Invitrogen) with 10% FBS (Atlanta Biologicals, At-
lanta, GA), penicillin (100 units/mL; Invitrogen) and
streptomycin (100 mg/mL; Invitrogen) in 96-well
round bottom cell culture plates with or without 1
mg/mL anti-CD3 antibody (BioXCell), or 5 mg/mL li-
popolysaccharide (LPS, Sigma-Aldrich) for 3 days. Six
hours before the end of cell culture, 1 mCi [3H]-thymi-
dine was added to each well. The proliferation of T cell
or B cell was measured by a scintillation counter.
Histological Analysis
Representative samples of liver, colon, and small
intestines were obtained from patients who underwent
transplantation and fixed in 10% neutral-buffered for-
malin. Samples were then embedded in paraffin, cut
into 5-mm thick sections, and stained with H&E. A
semiquantitative scoring system was used to account
for histologic changes consistent with the GVHD
signs in the colon and liver as previously described
[11]. Data was presented as individual GVHD target
organ scores as well as a composite score from all the
tissues. All slides for GVHD analysis were coded and
read in a blinded fashion. Images were visualized
with an Olympus BX45 microscope. Image acquisition
was performed with an Olympus DP70 digital camera
(400) and software package.
Mouse Serum Cytokine Analysis and
Intracellular Cytokine Staining
Mouse serum cytokine was analyzed following the
protocol of BD Cytometric Bead Array Mouse Th1/
Th2/Th17 Cytokine Kit (BD Biosciences).
Statistics
The recipient survival among groups in the
GVHD experiments was compared by log-rank test.
The t test was used for all the other experiments.RESULTS
Daily Treatment with LBH589 Accelerated
GVHD after Allogeneic BMT
Reduction of GVHD after treatment with pan-
HDACi SAHA indicates that HDAC can alleviate
1184 Biol Blood Marrow Transplant 18:1182-1190, 2012D. Wang et al.the pathogenesis of GVHD. LBH589 is also a pan-
HDACi but with much higher potency [10]. There-
fore, we originally hypothesized that LBH589 would
have a higher efficacy in the prevention of GVHD
when compared with SAHA.
Before evaluating the efficacy of LBH589 in
GVHD, we first tested its toxicity in recipients after
myeloablative conditioning and BM reconstitution to
determine the maximum tolerated dose. B/c mice
were lethally irradiated 1 day before adoptive transfer
of TCD-BM from B6 donors. Recipients were treated
every day with LBH589 from day 0 to 4 at 2.5, 5, 10, or
20 mg/kg body weight (BW). By monitoring recipient
survival, we found that treatment with 10 mg/kg
LBH589 or higher dose caused significant mortality
when compared with vehicle control (Figure 1A).
Treatment with 5 mg/kg LBH589 or lower dose
does not show significant toxicity, although some
mice died. To determine whether LBH589 affects do-
nor BM reconstitution, we compared donor B cell, T
cell, dendritic cell (DC), and neutrophil reconstitution
in recipient spleen at day 28 after BMT. As shown in
Figure 1B, daily treatment with 2.5 mg/kg BW
LBH589 did not compromise donor lymphocyte re-
constitution. In addition, the proliferative function of
splenic B cell and T cell was intact (Figure 1C).
Because LBH589 was toxic to allogeneic BMT re-
cipients when given a dose of 10 mg/kg or higher, we
decided to evaluate the efficacy of LBH589 in the pre-
vention of GVHD using 1.25 or 2.5 mg/kg doses every
day from day 0 to 4. Recipient survival and BW
changes were monitored beyond 100 days after
BMT. Daily treatment with LBH589 at 2.5 mg/kg
did not cause mortality or additional weight loss as
compared with vehicle control on recipients who un-
derwent transplantation with TCD-BM alone
(Figure 2). Unexpectedly, when T cells were added,
the treatment with LBH589 at either dose significantly
worsened GVHD, because treated recipients had ac-
celerated death and dramatic weight loss when com-
pared with GVHD controls (BM 1 T cell 1 PBS
group) (Figure 2A and B).Treatment with LBH589 Every Other Day had
Lower Toxicity but Still Accelerated GVHD
Accelerated GVHD associated with every day
treatment could have resulted from LBH589 toxicity
or enhanced T cell activation. To lower the potential
toxicity of LBH589, we decided to administer it every
other day for 2 weeks. No mortality was observed on
this treatment schedule when LBH589 was given at
2.5 to 7.5 mg/kg (Figure 3A). Although treatment at
7.5 mg/kg causes noticeably more weight loss than
that with vehicle control, all recipients treated with
LBH589 shortly recovered their BW to the levels of
those treated with vehicle control (Figure 3B). Weconclude that the every other day treatment causes
lower toxicity compared to every day treatment.
To assess the effect of LBH589 in the prevention
of GVHD, we treated the recipients with LBH589 ev-
ery other day at 2.5 mg/kg for 2 weeks, and found that
the treatment with such dose and schedule had no ap-
preciable toxicity in the recipients with TCD-BM
alone nor on GVHD in the recipients with TCD-
BM plus allogeneic T cells (Figure 4A and B). Further,
we evaluated the LBH589 efficacy in the every other
day schedule by increasing the dose to 5 mg/kg. Al-
though the every other day treatment with LBH589
at 5mg/kg for 2 weeks did not cause noticeable toxicity
on the TCD-BM group, such treatment significantly
accelerated GVHD in the recipients of T cells
(Figure 4C and D).
LBH589 and SAHA had an Opposite Effect on
GVHD
LBH589 is a pan-HDACi with much higher po-
tency than SAHA. Given that independent groups
showed that SAHA alleviates GVHD after allogeneic
BMT [7,9], it was highly unexpected to observe the
accelerated GVHD with LBH589 treatment
(Figures 2 and 4). To exclude the possibility that the
experimental systems we chose might contribute to
our unexpected results, we directly compared the ther-
apeutic effects of SAHA and LBH589 on GVHD pre-
vention. We used the same dose and schedule of
SAHA treatment shown to be effective in previously
published reports by others [7,8], and confirmed that
SAHA significantly alleviated GVHD in sharp
contrast with LBH589, which significantly
accelerated GVHD (Figure 5A and B). All compari-
sons were made between PBS vehicle, SAHA and
LBH589 treatment groups. The distinct outcomes
on GVHD resulted from the treatment with
LBH589 or SAHA were further supported by patho-
logic evidence. Figure 5C shows significantly increased
damage (P\ .01) in the liver from the LBH589 treated
recipients when compared with the ones that received
vehicle alone. In contrast, the treatment with SAHA
produced lower liver damage than observed in the
control group. We also examined pathologic changes
in the colon and small intestine, and found that the
pathologic scores were higher in the recipients treated
with LBH589 than those with vehicle control, al-
though the differences were not statistically significant
(data not shown). In conclusion, LBH589 and SAHA
had an opposite effect on GVHD development.
In Vivo T Cell Activation was Decreased by
SAHA, but Increased by LBH589
To understand the underlying mechanisms by
which LBH589 and SAHA had opposite effects on
GVHDdevelopment, we evaluated theT cell activation
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Figure 1. Toxicity of LBH589with every day treatment. B/c mice (n5 4-5) were lethally irradiated 1 day before bonemarrow transplant (BMT). On the
day of transplantation, 5 106 T cell depleted (TCD) B6 bonemarrow (BM) cells were transferred to B/c recipients via tail vein. Recipients were treated
with PBS vehicle or different dose of LBH589 daily from day 0 to 4 via i.p. injection. (A) Mice survival. (B) On day 28, recipients (n 5 5) treated with
vehicle control or LBH589 at 2.5 mg/kg BW were killed, and the percentages of donor B cells (B220), T cells (CD4/CD8), dendritic cell (DC;
CD11c), and neutrophils (CD11b/Gr-1) in the spleen were analyzed by flow cytometry. (C) The 4  105 splenic cells from recipient mice (n 5 5)
were stimulated with 1 mg/mL anti-CD3 or 5 mg/mL lipopolysaccharide (LPS) for 3 days. The proliferation of T cells or B cells was compared by
[3H]-thymidine incorporation. This experiment was repeated 3 times and similar phenomenon was observed. The representative data from one exper-
iment was shown. CPM, count per minute; n.s., no significant difference. *P\.05.
Biol Blood Marrow Transplant 18:1182-1190, 2012 1185HDACs in GVHDin response to alloantigens in vivo by measuring
TNF-a and IFN-g in recipient serum because either
inflammatory cytokine plays a critical role in GVHD
development. As shown in Figure 6A and B, the levels
of TNF-a and IFN-g were significantly lower in the
recipients treated with SAHA than those treated with
vehicle control, consistent with published reports byothers that SAHA reduces the inflammatory cytokines
[9]. In contrast, the levels of IFN-g and TNF-a were
significantly higher in the recipients treated with
LBH589 than those treated with vehicle control, sug-
gesting that LBH589 enhanced T cell activation
in vivo. We also compared other Th1/Th2/Th17 cy-
tokines like IL-2, IL-4, IL-6, IL-10, and IL-17, and
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Figure 2. Effect of LBH589with every day treatment on graft-versus-host disease (GVHD). B/c mice (n5 5-6) were lethally irradiated and the next day
underwent transplantation with 5 106 T cell depleted (TCD) B6 bone marrow (BM) cells with or without 1 106 T cells via tail vein. Recipients were
treated with PBS vehicle or different dose of LBH589 daily from day 0 to 4 via i.p. injection. Mice survival (A) and body weight (BW) (B) are shown. This
experiment was repeated 3 times and similar results were obtained. One representative experiment was shown here. BMT, bone marrow transplant.
*P\.05; **P\.01.
1186 Biol Blood Marrow Transplant 18:1182-1190, 2012D. Wang et al.observed similar levels among all experimental groups
(data not shown).
Donor T cell expansion and subsequent migration
into target organs are essential for the development of
GVHD. We thus measured donor T cells in recipi-
ents’ spleens on day 14 after BMT, and found that
treatment with LBH589 reduced the number of donor
T cells in the spleen, whereas SAHA had no effect
(Figure 7A). Because migration of activated T cells
into GVHD target organs primarily relies on chemo-
kine receptors expression, we compared the expression
of chemokine receptors on donor T cells in the recip-
ients treated with LBH589, SAHA, or vehicle control.
Among the receptors (CXCR3, a4b7, and CCR6)
tested, we found that donor CD41 and CD81 T cells
expressed significantly higher levels of CXCR3 after
LBH589 treatment (Figure 7B). Given that CXCR3
is preferentially expressed on Th1 cells, these data
are consistent with elevated Th1 cytokines (IFN-g
and TNF-a) in the recipients treated with LBH589
(Figure 5). As a consequence, significantly higher
numbers of donor CD41 and CD81 T cells were
found in the liver of the recipients treated with
LBH589 compared to those with vehicle control0 5 10 15 20 25 30
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Figure 3. Toxicity of LBH589 with every other day treatment. B/c mice (n5 4
cell depleted (TCD) B6 bonemarrow (BM) cells via tail vein. Recipients were tre
day 0 to 13 via i.p. injection. Mice survival (A) and body weight (BW) (B) are
obtained. One representative experiment was shown. BMT, bone marrow tra(Figure 7C). Taken together, treatment with
LBH589 increased T cell activation and migration to
GVHD target organ liver in particular, which likely re-
sulted in accelerated GVHD after allogeneic BMT.
To exclude the possibility that LBH589 treatment
led to BM failure, we compared the percentage of do-
nor BM-derived cells in the spleen at day 13. As seen in
Figure 7D and E, the percentage of H-2kb1 cell pop-
ulation (donor BM-derived) were very similar among
the 3 experimental groups.DISCUSSION
A pan-HDACi, SAHA, was shown to alleviate
GVHD after allogeneic BMT in various mouse
models [5,7-9]. Here we tested another highly potent
pan-HDACi, LBH589, in the prevention of GVHD
after allogeneic BMT with the expectation that
LBH589 would diminish GVHD with a high efficacy.
Contrary to our expectation, LBH589 accelerated
rather than alleviated GVHD. The accelerated
GVHD was associated with increased secretion of
Th1 inflammatory cytokines. Pathological T cell infil-
tration in the liver was also increased by LBH589,5 10 15 20 25 30
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Figure 4. Effect of LBH589 with every other day treatment on graft-versus-host disease (GVHD). B/c mice (n5 5-6) were lethally irradiated and un-
derwent transplantation with 5 106 T cell depleted (TCD) B6 bone marrow (BM) cells with either 0.25 106 or 1 106 B6 CD25 T cells. Recipients
were treated for 12 days every other day via i.p. injection with PBS vehicle or LBH589 (2.5 mg/kg body weight [BW] for 0.25 106 T cell recipients and
5 mg/kg BW for 1 106 T cell recipients). Mice survival (A, C) and BW (B, D) are shown here. The experiment was repeated 3 times and similar results
were observed. One representative experiment was shown. BMT, bone marrow transplant; n.s., no significant difference; **P\.01.
Biol Blood Marrow Transplant 18:1182-1190, 2012 1187HDACs in GVHDlikely through upregulation of CXCR3 expression on
donor T cells.
It is known that Th1 cytokines, including IFN-g
and TNF-a, are the critical effectors for acute
GVHD, although recent reports showed that IFN-g
has dual effects in the immune regulation [12-14].
IFN-g is secreted by activated donor T cells, and
increased serum levels of IFN-g were related to
acute GVHD [15,16]. TNF-a was normally secreted
by host antigen presenting cells (APC) and donor T
cells [17]. Higher TNF-a level indicated higher host
APC activity, which was correlated with increased se-
verity of GVHD. Here, we show that LBH589 treat-
ment significantly increased IFN-g and TNF-a level
in serum from recipients treated with LBH589. These0 20 40 60
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Figure 5. Effect of LBH589 and suberoylanilide hydroxamic acid (SAHA) on
underwent transplantation with 5 106 T cell depleted (TCD) B6 bonemarrow
PBS vehicle, SAHA (25 mg/kg body weight [BW], daily treatment from day 0 to
injection. (A) Mice survival was the combined data from 3 independent experim
the repeated experiments. (C) GVHD pathological score of mice livers from th
transplant. **P\.01; ***P\.001.elevated inflammatory cytokines likely contributed to
accelerated GVHD. In addition, our in vitro experi-
ments showed that at certain doses, LBH589 signifi-
cantly increased IFN-g secretion, proliferation of T
cells, and the antigen presentation ability of DC
(Supplementary Figures 1 and 2), consistent with our
observation in vivo (Figure 6). Therefore, the
LBH589 doses used in vivo may fall in the concentra-
tion range that promoted T cell activation. Because
LBH589 was toxic at high doses in vivo, we could
not demonstrate the protective effect of LBH589 in
GVHD. In accordance with our observation regarding
the effect of LBH589 on cytokine production, Wang
et al. [18] recently reported that LAQ824, another
pan-HDACi, augmented inflammatory responses in60
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Figure 6. Effect of LBH589 and suberoylanilide hydroxamic acid
(SAHA) on cytokine production. B/c mice were lethally irradiated and
underwent transplantation with 5  106 T cell depleted (TCD) B6
bone marrow (BM) cells with or without 1  106 T cells. Recipients
were treated with PBS vehicle, SAHA (25mg/kg body weight [BW], daily
treatment from day 0 to 7), or LBH589 (1.25 mg/kg BW, every other day
from day 0 to 12) via i.p. injection. Mice were killed on day 13, and serum
IFN-g (A) and TNF-a (B) were analyzed by flow cytometric bead array.
The data shown here are pooled from 2 replicate experiments (n 5 8)
with the same setting. BMT, bone marrow transplant. ***P\.001.
1188 Biol Blood Marrow Transplant 18:1182-1190, 2012D. Wang et al.macrophages through transcriptional regulation of
IL-10. SAHA does not always downregulate the in-
flammatory response; it was reported to suppress the
LPS-induced mRNA expression of the proinflamma-
tory mediators Edn1, CCL7/MCP-3, and Il-12p40,
but amplify the expression of the proatherogenic fac-
tors Cox-2 and Pai-1/serpine1 in primary mouse
BM-derived macrophages [19]. Thus, the effect of
pan-HDACi on inflammation may be drug and dis-
ease-specific.
When comparing T cell expansion in spleen and T
cell infiltration in GVHD target organs at day 14, we
found that there were much less donor T cells in
the recipient spleen after the LBH589 treatment
(Figure 7), but more donor T cells infiltrated the liver.
Consistent with this finding, pathological analysis
showed higher GVHD scores in the livers from the
LBH589 treated group (Figure 5C). Less splenic T
cells might reflect less T cell expansion, or more exten-
sive T cell migration from the spleen to the GVHD
target organs upon LBH589 treatment. In fact, we
found that after the LBH589 treatment, significantly
more donor T cells expressed CXCR3, a chemokine
receptor that mediates T cell migration to the liver
and the intestine [20]. We did not observe more severe
GVHD in the colon and small intestine in LBH589
treated recipients. It was likely due to the difference
in the spatiotemporal expression of cytokine and che-
mokine gradients. After total body irradiation, the in-
crease of proinflammatory cytokines and the forming
of chemokine gradients (CXCL9-11) may occur ear-
lier in the liver than in the gut. In addition, the expres-
sion of T cell gut homing-receptor, a4b7, was not
altered by LBH589 treatment (data not shown).
Therefore, we surmised that LBH589 aggravated
GVHD by increasing T cell activation, Th1 cytokine
production, and T cell migration to the recipient liver
through upregulating CXCR3 expression.Previous studies by others have shown that pan-
HDACis have therapeutic effect on many inflamma-
tory disease models. Glauben et al. [3] showed that
oral administration of either valproic acid (another
HDACi) or SAHA reduced the disease severity in dex-
tran sulfate sodium-induced colitis in mice. The re-
duction of disease severity was associated with
a marked suppression of colonic proinflammatory cy-
tokines and apoptosis of lamina propria lymphocytes.
Three other groups showed that SAHA alleviated
GVHD after allogeneic BMT [5,7-9]. It appears that
our data are contradictory to those published;
however, we believe that the distinct outcomes with
SAHA and LBH589 can be readily reconciled.
We all used pan-HDACi without considering the
functional difference of individual HDAC members.
Actually, HDACmembers have similar or opposite ef-
fects on the regulation of immune response. Condi-
tional deletion of HDAC1 in T cells leads to
enhanced airway inflammation and increased Th2 cy-
tokine production [21]. HDAC2 activity is indispensi-
ble to control chronic obstructive pulmonary disease
by corticosteroid [22,23]. A recent report showed
that HDAC6-deficiency increases the suppressive po-
tency of regulatory T cells [24,25], whereas our
unpublished data indicated that HDAC11-deficiency
resulted in T cell hyperactivation leading to increased
severity of GVHD in mice. When a pan-HDACi was
tested, what we observed is a compound effect on all
11 HDAC members. Considering the wide range of
potency of individual HDACis on different HDAC
members, and that each HDAC member plays a dis-
tinct role, it is plausible that 2 inhibitors would likely
have distinct effects on a certain disease. Specifically,
SAHA and LBH589 have very different potency in in-
hibiting each member of the HDAC family (eg,
LBH589 inhibits HDAC11 40-fold more potently
than SAHA) [10]. Given that HDAC11may negatively
regulate T cell function as supported by our unpub-
lished data, effective blockade of HDAC11 by
LBH589, but not by SAHA, could contribute to the
different GVHD outcome after treatment with
LBH589 vs SAHA.
In addition, the substrate of HDACs are not lim-
ited to histones [26]. There are more than 1750 non-
histone substrates that make the effect of HDACi
even more complex [27]. Given the paucity of knowl-
edge on the functions of nonhistone substrates, it is
currently impossible to precisely predict the effect
of HDACis at the cellular level until the role of indi-
vidual HDAC is uncovered, and isoform-specific
HDACis are developed. Finally, LAQ824, another
pan-HDACi derived from hydroxamic acid, enhanced
antitumor activity of tumor antigen-specific lympho-
cytes both in vitro and in vivo [28]. This is consistent
with our finding that LBH589 enhanced allogeneic
T cell activation in vivo. The LBH589 structure is
Figure 7. Effect of LBH589 and suberoylanilide hydroxamic acid (SAHA) on donor T cell expansion andmigration in vivo. B/c mice (n5 4) were lethally
irradiated and underwent transplantation with 5  106 T cell depleted B6 bone marrow (BM) cells with or without 1  106 T cells. Recipients were
treated with PBS vehicle, SAHA (25 mg/kg body weight [BW], daily treatment from day 0 to 7) or LBH589 (1.25 mg/kg BW, every other day from
day 0 to 12) via i.p. injection. Mice were killed on day 13. Splenic T cell number (A), CXCR3 expression on splenic donor T cells (B), and liver T cell
infiltration (C) were analyzed by flow cytometry. The data shown are pooled from 2 replicate experiments (n 5 8). (D) The flow cytometry data of
H-2kb1 CD4-CD8- cells in the spleen of each group are shown. The data of 1 mouse from each group was shown here. Only the cells in live gate
were studied. (E) The average percentage of H-2kb1 cells in spleen are shown here. Only the cells in live gate were studied. The data shown was pooled
from 2 replicate experiments (n 5 8). n.s., no significant difference; *P\.05; **P\.01; ***P\.001.
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LBH589 IC50 to HDAC members is quite similar to
LAQ824. This may be the reason why both drugs
improved T cell activation in vivo.
In summary, we evaluated the effect of LBH589 on
the prevention of GVHD and found that LBH589 ac-
celerated rather than alleviated GVHD after alloge-
neic BMT in mice. The accelerated GVHD was
associated with increased systemic Th1 cytokines and
donor T cell infiltration in the recipient liver. Thisstudy highlights the distinct effects of pan-HDACi
on allogeneic BMT, and demonstrates that LBH589
(Panobinostat) could have an adverse effect on
GVHD or other inflammatory diseases if used in
a treatment scheme to replace other HDACis. Thus,
caution must be taken in consideration not to assume
that pan-HDACis would lead to similar therapeutic ef-
fects. Instead, the information learned from this study
strongly encourages investigations on the function of
individual HDAC members, and the development of
1190 Biol Blood Marrow Transplant 18:1182-1190, 2012D. Wang et al.isoform-specific HDACis for higher efficacy and bet-
ter selectivity.ACKNOWLEDGMENTS
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Supplementary Figure 1. Effect of LBH589 on mouse T cell in vitro. Purified T cells from B6 mice were labeled with CFSE and stimulated with plate
bound anti-CD3 (10 mg/mL) and soluble anti-CD28 (1 mg/mL) with LBH589 at indicated concentrations for 3 days. Cells were then stimulated with PMA
(50 ng/mL) plus ionomycin (500 ng/mL) for 4 hours. Golgi Plug was added to cell culture at 1 mL/well 2 hours after starting cell culture. (A) The cells were
harvested and IFN-g secretion was measured by flow cytometry. (B) T cell proliferation was measured by CFSE dilution and normalized to positive
control. Data are shown on gated CD4+ cells, and similar results were seen on CD8+ cells (not shown). This experiment was repeated 2 times and
the results were very similar. One representative experiment was shown here. n.s., no significant difference. *P\.05; **P\.01.
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Supplementary Figure 2. LBH589 enhanced the antigen presenta-
tion ability of dendritic cell (DC) at certain dose range. B/c bone mar-
row-derived DCs were generated by adding supernatant of J558L
(including granulocyte macrophage-colony stimulating factor) to the
cell culture. On day 5, DCs were treated with LBH589 doses (serial di-
lution from 12.5 nM to 0.39 nM) for 2 hours before adding lipopolysac-
charide (LPS). On day 6, DCs was washed and mixed leukocyte reaction
was set up using B6 T cells as responder and irradiated DCs as stimula-
tor. T cell proliferation was measured by [3H]-thymidine incorporation.
The repeated experiment showed the same trend.
